The article by Ozdemir et al1 sheds light on important questions with which we struggle in treating patients with ischemic stroke. The administration of recombinant tissue plasminogen activator (rtPA) according to standard protocols frequently excludes patients who might benefit from such treatment. It is estimated that only 3% to 8% of eligible patients with ischemic stroke receive rtPA.2 Studies that expand the use of rtPA hold promise for increasing that percentage.
Totah A. Thrombolysis, Fluctuations, and Protocol Expansions. Arch Neurol. 2009;66(3):416-421. doi:10.1001/archneurol.2008.590